Get the Stockscreener App
57.65
3.53%
-2.11
Pre-market:
58.00
0.35
+0.61%
Protagonist Therapeutics Inc stock is traded at $57.65, with a volume of 2.21M.
It is down -3.53% in the last 24 hours and up +54.06% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$59.76
Open:
$59.575
24h Volume:
2.21M
Relative Volume:
2.86
Market Cap:
$3.54B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
22.00
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
+49.93%
1M Performance:
+54.06%
6M Performance:
+26.29%
1Y Performance:
+93.00%
1-Day Range:
$56.66
$60.60
1-Week Range:
$37.92
$60.60
52-Week Range:
$24.22
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
57.65 | 3.54B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - Yahoo Finance
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com
Protagonist Therapeutics price target raised to $76 from $60 at Truist - TipRanks
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success - Yahoo Finance
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital - TipRanks
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - Yahoo Finance
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up - Simply Wall St
Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright - TipRanks
Protagonist Therapeutics Gets IBD Stock Rating Upgrade - Investor's Business Daily
10 Firms Buck Market Bloodbath on Monday - Insider Monkey
Protagonist Therapeutics Earns Relative Strength Rating Upgrade - Inkl
Protagonist Therapeutics’ (PTGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - Investor's Business Daily
BTIG maintains Buy on Protagonist Therapeutics, target at $73 By Investing.com - Investing.com Canada
Truist raises Protagonist Therapeutics target to $76 - Investing.com
Truist raises Protagonist Therapeutics target to $76 By Investing.com - Investing.com UK
Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Benzinga
Truist Securities Adjusts Price Target on Protagonist Therapeutics to $76 From $60, Keeps Buy Rating - Marketscreener.com
Protagonist Therapeutics rises as bowel disease drug succeeds mid-stage study - TradingView
Protagonist reports top line results from Phase 2b study of icotrokinra - TipRanks
PTGX stock soars to 52-week high, reaching $50.18 - Investing.com India
Why Protagonist Therapeutics Shares Are Under Pressure - TipRanks
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis - ACCESS Newswire
BTIG maintains Buy on Protagonist Therapeutics, target at $73 - Investing.com India
JMP reiterates $61 target for Protagonist Therapeutics stock - Investing.com
JMP reiterates $61 target for Protagonist Therapeutics stock By Investing.com - Investing.com Canada
Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A New Benchmark for Oral Therapies - TipRanks
Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of Icotrokinra - TipRanks
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $55.89 Average Price Target from Analysts - Defense World
Protagonist Therapeutics Inc (PTGX) Announces Promising Phase 3 Results for Icotrokinra in Psoriasis Treatment - GuruFocus.com
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock - Defense World
Positive Phase III VERIFY results of rusfertide in PV - The Pharma Letter
H.C. Wainwright maintains Buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy rating on Protagonist Therapeutics stock - Investing.com India
Truist maintains Buy on Protagonist Therapeutics, $60 target By Investing.com - Investing.com Canada
Protagonist Therapeutics (NASDAQ:PTGX) Receives “Buy” Rating from HC Wainwright - Defense World
Protagonist Therapeutics: Buy Rating Affirmed on Rusfertide’s Phase 3 Success and Market Potential - TipRanks
Protagonist Therapeutics: Strong Buy Rating Backed by Promising Phase 3 Results and Robust Financial Outlook - TipRanks
Protagonist Therapeutics: Positive VERIFY Trial Results and Promising Financial Prospects Justify Buy Rating - TipRanks
Protagonist Therapeutics CFO Ali Asif reports stock sale - MSN
Takeda/Protagonist’s Rusfertide Could Be A Main Character In PV After Phase III Data - Citeline News & Insights
Truist maintains Buy on Protagonist Therapeutics, $60 target - Investing.com
Protagonist Therapeutics price target raised to $73 from $67 at BTIG - TipRanks
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - AOL
News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat - Yahoo Finance
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PATEL DINESH V PH D | President and CEO |
Mar 05 '25 |
Option Exercise |
4.21 |
24,000 |
101,040 |
564,260 |
| PATEL DINESH V PH D | President and CEO |
Feb 19 '25 |
Sale |
38.18 |
5,359 |
204,607 |
540,260 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 27 '24 |
Option Exercise |
8.04 |
26,000 |
209,040 |
62,444 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Option Exercise |
8.04 |
5,529 |
44,453 |
51,973 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 27 '24 |
Sale |
44.70 |
26,000 |
1,162,280 |
46,444 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Sale |
45.60 |
5,529 |
252,122 |
46,444 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Option Exercise |
7.75 |
175,000 |
1,356,000 |
359,611 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Option Exercise |
12.17 |
30,450 |
370,576 |
286,174 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Sale |
46.04 |
103,437 |
4,762,239 |
256,174 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Sale |
45.50 |
19,191 |
873,190 |
266,983 |
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):